Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 January 2006 to 31 January 2006 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC) 
Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 January 2006 to 31 January 2006 
(Decisions taken pursuant to Article 34 of Directive 2001/83/EC [1] or Article 38 of Directive 2001/82/EC [2]) 
(2006/C 46/04) 
Ã¢&#x20AC;&#x201D; Issuing, maintenance or modification of a national marketing authorisation 
Date of the decision | Name(s) of the medicinal product | Holder(s) of the marketing authorization | Member State concerned | Date of notification | 
9.1.2006 | Actilyse | See Annex I | See Annex I | 10.1.2006 | 
24.1.2006 | Ionsys | Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse | This Decision is addressed to the Member States | 25.1.2006 | 
24.1.2006 | Exubera | Aventis/Pfizer EEIG, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom | This Decision is addressed to the Member States | 25.1.2006 | 
31.1.2006 | Macugen | Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom | This Decision is addressed to the Member States | 1.2.2006 | 
[1] OJ L 311, 28.11.2001, p. 67. 
[2] OJ L 311, 28.11.2001, p. 1. 
-------------------------------------------------- 
ANNEX I 
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, CONTENT AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
Member State | Marketing Authorisation Holder | Invented name | Strength | Pharmaceutical Form | Route of administration | Content (concentration) | 
Austria | Boehringer Ingelheim Austria GmbH | Actilyse | 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Belgium | n.v. Boehringer Ingelheim s.a. | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Cyprus | Cyprus Pharm. Organization Ltd. | Actilyse | 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
Czech Republic | Boehringer Ingelheim International GmbH | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
Denmark | Boehringer Ingelheim International GmbH | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Estonia | Boehringer Ingelheim International GmbH | Actilyse | 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
Finland | Boehringer Ingelheim International GmbH | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
France | Boehringer Ingelheim, France | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Germany | Boehringer Ingelheim Pharma KG | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Greece | Boehringer Ingelheim Hellas AE | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Hungary | Boehringer Ingelheim International GmbH | Actilyse | 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
Ireland | Boehringer Ingelheim Ltd, Royaume-Uni | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Italy | Boehringer Ingelheim Italia spa | Actilyse | 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Latvia | Boehringer Ingelheim International GmbH | Actilyse | 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
Lituania | Boehringer Ingelheim International GmbH | Actilyse | 50 mg | Povder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
Luxembourg | n.v. Boehringer Ingelheim s.a., Belgique | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Malta | Boehringer Ingelheim Ltd., Royaume-Uni | Actilyse | 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Netherlands | Boehringer Ingelheim b.v. | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Poland | Boehringer Ingelheim International GmbH | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for infusion | Intravenous use | 1 mg/ml | 
Portugal | Boehringer Ingelheim, Lda | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Slovakia | Boehringer Ingelheim International GmbH | Actilyse | 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Slovenia | Boehringer Ingelheim International GmbH | Actilyse | 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
Spain | Boehringer Ingelheim International GmbH | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Sweden | Boehringer Ingelheim International GmbH | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
United Kingdom | Boehringer Ingelheim Ltd. | Actilyse | 10, 20, 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Iceland | Boehringer Ingelheim International GmbH | Actilyse | 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml or 2 mg/ml | 
Norway | Boehringer Ingelheim International GmbH | Actilyse | 10, 20 50 mg | Powder and solvent for solution for injection and infusion | Intravenous use | 1 mg/ml | 
-------------------------------------------------- 
